(34.232.51.240)
Users online: 2072    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacology and Pharmacodynamics
Year : 2020, Volume : 12, Issue : 1
First page : ( 29) Last page : ( 33)
Print ISSN : 0975-4407. Online ISSN : 2321-5836.
Article DOI : 10.5958/2321-5836.2020.00007.5

The Influence of Pharmacogenetics in Cancer Chemotherapy

Jisha K, Venkateswaramurthy N.*, Sambathkumar R

Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam-638183, Tamil Nadu, India

*Corresponding Author E-mail: venkateswaramurthy.n@jkkn.org

Abstract

Pharmacogenomics is an upcoming field that focusing on the genetic variations related to drug action. The cellular abnormalities arise from the inter individual genetic modifications, through the variation in genetic sequences or due to the modification in gene activation or DNA-related proteins. The pharmacogenomics study deals with the variation that provides the therapy more effective and safer by determining selection and dosing of drugs for an inter individuals and the medication demonstrates unpredictable efficacy and toxicity linked to the medication in the individual patients. Genetic polymorphisms in phase I and phase II enzymes may explain part of the inter-individual variation observed in anticancer drug pharmacokinetics and pharmacodynamics. There are numerous therapy choices for many kinds of cancer. The selection of the most suitable treatment would benefit from guidelines to enable the initiation of effective treatment as soon as possible. Failed therapy or unacceptable toxicity can considerably decrease the ideal therapeutic window resulting in a change in medication or dose. Consequently, it will be crucial to elucidate the role of pharmacogenomics in individualizing treatment in the near future research including genotype-driven clinical trials. Furthermore, trials involving gene/SNP detection approaches will be crucial for chemotherapy where there are no known validated markers to identify fresh prospective markers.

Top

Keywords

Pharmacogenomics, Cellular abnormalities, Genetic polymorphisms, Therapeutic window, Prospective markers.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
452,101,652 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.